Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
<h4>Objective</h4>We performed a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials evaluating suvorexant for primary insomnia.<h4>Methods</h4>Relevant studies were identified through searches of PubMed, databases of the Cochrane Librar...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0136910 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850113667990814720 |
|---|---|
| author | Taro Kishi Shinji Matsunaga Nakao Iwata |
| author_facet | Taro Kishi Shinji Matsunaga Nakao Iwata |
| author_sort | Taro Kishi |
| collection | DOAJ |
| description | <h4>Objective</h4>We performed a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials evaluating suvorexant for primary insomnia.<h4>Methods</h4>Relevant studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations through June 27, 2015. We performed a systematic review and meta-analysis of suvorexant trial efficacy and safety outcomes. The primary efficacy outcomes were either subjective total sleep time (sTST) or subjective time-to-sleep onset (sTSO) at 1 month. The secondary outcomes were other efficacy outcomes, discontinuation rate, and individual adverse events. The risk ratio, number-needed-to-treat/harm, and weighted mean difference (WMD) and 95% confidence intervals (CI) based on a random effects model were calculated.<h4>Results</h4>The computerized literature database search initially yielded 48 results, from which 37 articles were excluded following a review of titles and abstracts and another eight review articles after full-text review. Thus, we identified 4 trials that included a total of 3,076 patients. Suvorexant was superior to placebo with regard to the two primary efficacy outcomes (sTST: WMD = -20.16, 95% CI = -25.01 to -15.30, 1889 patients, 3 trials, sTSO: WMD = -7.62, 95% CI = -11.03 to -4.21, 1889 patients, 3 trials) and was not different from placebo in trial discontinuations. Suvorexant caused a higher incidence than placebo of at least one side effects, abnormal dreams, somnolence, excessive daytime sleepiness/sedation, fatigue, dry mouth, and rebound insomnia.<h4>Conclusions</h4>Our analysis of published trial results suggests that suvorexant is effective in treating primary insomnia and is well-tolerated. |
| format | Article |
| id | doaj-art-c36afc7a63654ef5aafda03e4555d956 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-c36afc7a63654ef5aafda03e4555d9562025-08-20T02:37:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013691010.1371/journal.pone.0136910Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.Taro KishiShinji MatsunagaNakao Iwata<h4>Objective</h4>We performed a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials evaluating suvorexant for primary insomnia.<h4>Methods</h4>Relevant studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations through June 27, 2015. We performed a systematic review and meta-analysis of suvorexant trial efficacy and safety outcomes. The primary efficacy outcomes were either subjective total sleep time (sTST) or subjective time-to-sleep onset (sTSO) at 1 month. The secondary outcomes were other efficacy outcomes, discontinuation rate, and individual adverse events. The risk ratio, number-needed-to-treat/harm, and weighted mean difference (WMD) and 95% confidence intervals (CI) based on a random effects model were calculated.<h4>Results</h4>The computerized literature database search initially yielded 48 results, from which 37 articles were excluded following a review of titles and abstracts and another eight review articles after full-text review. Thus, we identified 4 trials that included a total of 3,076 patients. Suvorexant was superior to placebo with regard to the two primary efficacy outcomes (sTST: WMD = -20.16, 95% CI = -25.01 to -15.30, 1889 patients, 3 trials, sTSO: WMD = -7.62, 95% CI = -11.03 to -4.21, 1889 patients, 3 trials) and was not different from placebo in trial discontinuations. Suvorexant caused a higher incidence than placebo of at least one side effects, abnormal dreams, somnolence, excessive daytime sleepiness/sedation, fatigue, dry mouth, and rebound insomnia.<h4>Conclusions</h4>Our analysis of published trial results suggests that suvorexant is effective in treating primary insomnia and is well-tolerated.https://doi.org/10.1371/journal.pone.0136910 |
| spellingShingle | Taro Kishi Shinji Matsunaga Nakao Iwata Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. PLoS ONE |
| title | Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. |
| title_full | Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. |
| title_fullStr | Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. |
| title_full_unstemmed | Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. |
| title_short | Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. |
| title_sort | suvorexant for primary insomnia a systematic review and meta analysis of randomized placebo controlled trials |
| url | https://doi.org/10.1371/journal.pone.0136910 |
| work_keys_str_mv | AT tarokishi suvorexantforprimaryinsomniaasystematicreviewandmetaanalysisofrandomizedplacebocontrolledtrials AT shinjimatsunaga suvorexantforprimaryinsomniaasystematicreviewandmetaanalysisofrandomizedplacebocontrolledtrials AT nakaoiwata suvorexantforprimaryinsomniaasystematicreviewandmetaanalysisofrandomizedplacebocontrolledtrials |